(UroToday.com) The combination of cisplatin-based chemotherapy with immune checkpoint inhibitors has previously been extensively investigated in urothelial carcinoma. Using this combination in the neoadjuvant setting for patients with muscle-invasive urothelial carcinoma might improve pathological response but carries the risk of increased perioperative morbidity. At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Richard Cathomas presented preliminary results of SAKK 06/17 assessing safety and efficacy using perioperative cisplatin/gemcitabine plus durvalumab for patients with muscle-invasive urothelial carcinoma.